公开(公告)号：US11666594B2

公开(公告)日：2023-06-06

申请号：US17065242

申请日：2020-10-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02 ,  A61K47/68 ,  A61K31/7076

CPC classification number: A61K31/7084 ,  A61K31/7076 ,  A61K47/6807 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US10738004B2

公开(公告)日：2020-08-11

申请号：US16331962

申请日：2017-09-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Nobuyuki Negoro ,  Masashi Yamasaki ,  Takahiro Tanaka ,  Naomi Kitamoto

IPC: C07C317/46 ,  A61K31/235 ,  A61P1/16 ,  A61P9/10 ,  A61P37/02 ,  A61P29/00 ,  A61P25/02 ,  A61P43/00

Abstract: Provided is a compound, such as ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl) -3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof, having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI).

公开(公告)号：US09828357B2

公开(公告)日：2017-11-28

申请号：US15356906

申请日：2016-11-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro ,  Taisuke Katoh ,  Masashi Yamasaki ,  Takahiro Tanaka ,  Naomi Kitamoto

IPC: C07D317/72 ,  C07C317/12 ,  C07D309/28 ,  C07C317/44 ,  C07C317/46

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.

公开(公告)号：US20160159773A1

公开(公告)日：2016-06-09

申请号：US14909427

申请日：2014-07-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Morihisa Saitoh ,  Takatoshi Yogo ,  Taku Kamei ,  Norihito Tokunaga ,  Yusuke Ohba ,  Takafumi Yukawa

IPC: C07D401/14 ,  C07D413/14

CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.